Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc reports results for the quarter ended in December - Earnings Summary

* Abcellera Biologics Inc  ABCL.OQ  reported a quarterly
adjusted
loss of 17 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -10 cents.  The mean expectation of ten analysts for the
quarter was for a loss of 13 cents per share. Wall Street
expected results to range from -20 cents to -11 cents per share.
    * Revenue fell 57.4% to $9.18 million from a year ago;
analysts
expected $8.88 million. 
    * Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 17 cents​.
    * The company reported a quarterly loss of $47.15 million.
    * Abcellera Biologics Inc shares had fallen by 7.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Abcellera
Biologics Inc is $17.00 

This summary was machine generated from LSEG data February 21 at
10:50 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.13          -0.17          Missed
 Sep. 30 2023      -0.13          -0.10          Beat
 Jun. 30 2023      -0.13          -0.11          Beat
 Mar. 31 2023      -0.14          -0.14          Met

Recent news on AbCellera Biologics

See all news